Targeting TIM-3 for hematological malignancy: latest updates from the 2022 ASH annual meeting

被引：6
|
作者：
Tan, Jiaxiong [1 ,2 ]
Tan, Huo [1 ]
Li, Yangqiu [2 ]
机构：
[1] Guangzhou Med Univ, Affiliated Hosp 5, Dept Hematol, Guangzhou 510700, Peoples R China
[2] Jinan Univ, Inst Hematol, Sch Med, Key Lab Regenerat Med,Minist Educ, Guangzhou 510632, Peoples R China
来源：
EXPERIMENTAL HEMATOLOGY & ONCOLOGY | 2023年 / 12卷 / 01期
基金：
中国国家自然科学基金;
关键词：
TIM-3; Gal-9; Immunotherapy; Hematological malignancies;
D O I：
10.1186/s40164-023-00421-2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
T cell immunoglobulin domain and mucin domain-3 (TIM-3) is an important immune checkpoint (IC) protein in cancer immunosuppression that is considered a novel target for immunotherapy. Moreover, TIM-3, an immuno-myeloid regulator, is highly expressed on the cells of several solid tumors and myeloid leukemia stem cells (LSCs). TIM-3 blockade was shown to have dual effects for directly inhibiting leukemia cells and restoring T cell activation. We summarize several of the latest reports on the role of TIM-3 in immunotherapy for hematological malignancies from the 2022 ASH Annual Meeting (ASH2022).
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Venetoclax-based therapy for relapsed or refractory acute myeloid leukemia: latest updates from the 2022 ASH annual meeting
    Gong, Xubo
    Zhang, Yi
    He, Xin
    Moloudizargari, Milad
    Yu, Teng
    Wang, Lin
    Liu, Weiwei
    Jin, Lan
    Xu, Huiying
    Xu, Yang
    Tao, Zhihua
    Qian, Wenbin
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [22] CAR-NK cell therapy: latest updates from the 2024 ASH annual meeting
    Kong, Ran
    Liu, Bingyu
    Wang, Hua
    Lu, Tiange
    Zhou, Xiangxiang
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
  • [23] Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting
    Guangcai Zhong
    Ran Kong
    Shi Feng
    Cong Wang
    Qingbo Hao
    Weilin Xie
    Xiangxiang Zhou
    Journal of Hematology & Oncology, 17
  • [24] Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting
    Zhong, Guangcai
    Kong, Ran
    Feng, Shi
    Wang, Cong
    Hao, Qingbo
    Xie, Weilin
    Zhou, Xiangxiang
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [25] Menin inhibitors for acute myeloid leukemia: latest updates from the 2023 ASH Annual Meeting
    An, Zhuo-Yu
    Zhang, Xiao-Hui
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2024, 17 (01)
  • [26] Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
    Ji-nuo Wang
    Tianning Gu
    Yongxian Hu
    He Huang
    Experimental Hematology & Oncology, 11
  • [27] Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting
    Wang, Ji-Nuo
    Gu, Tianning
    Hu, Yongxian
    Huang, He
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2022, 11 (01)
  • [28] Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
    Hou, Jing-Zhou
    Ye, Jing Christine
    Pu, Jeffrey J.
    Liu, Hongtao
    Ding, Wei
    Zheng, Hong
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [29] Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting
    Jing-Zhou Hou
    Jing Christine Ye
    Jeffrey J. Pu
    Hongtao Liu
    Wei Ding
    Hong Zheng
    Delong Liu
    Journal of Hematology & Oncology, 14
  • [30] Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting
    Li, Xingchen
    Zhang, Peng
    Sun, Hao
    Han, Lijie
    Jiang, Zhongxing
    Yu, Jifeng
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2023, 23 (12) : 1193 - 1195
12345